PPT-Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

Author : debby-jeon | Published Date : 2017-12-10

or 3 LONESTAR2 Phase 2 Treatment Experienced Lawitz E et al Hepatology 20156176975 Source Lawitz E et al Hepatology 20156176975 Sofosbuvir PEG RBV

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Sofosbuvir + Peginterferon + Ribavirin i..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2: Transcript

or 3 LONESTAR2 Phase 2 Treatment Experienced Lawitz E et al Hepatology 20156176975 Source Lawitz E et al Hepatology 20156176975 Sofosbuvir PEG RBV . ELECTRON (Overview): 6 parts, 22 arms. Phase . 2. Treatment. Naïve and Treatment . Experienced. Source: . Gilead Sciences, . Inc. Sofosbuvir. Summary of ELECTRON Trials Design (1 of 2). Part 1 . - . Treatment –Experienced Genotype . 1 . ASPIRE Trial. Phase . 3. Treatment. . Experienced. Z. euzem. S. , . et al. . Gastroenterol. . 2014;146:430-41.. Source: . Zeuzem. S. , et al. . Gastroenterol. (. Epclusa. ). Prepared by. : H. Nina Kim, MD MSc and David . Spach. , MD. Last . Updated: . July . 8, . 2016. Background and Dosing. Sofosbuvir-Velpatasvir. (. Epclusa. ). Sofosbuvir-Velpatasvir. (. versus. . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. Manns. . MP, et. al. Lancet. 2001;358:958-65. Peginterferon alfa-2b + Ribavirin . versus . Interferon alfa-2b + Ribavirin . Pegasys. ). Prepared by: David Spach, MD & H. Nina Kim, MD. Last Updated: February . 14, . 2014. Background and Dosing. Peginterferon alfa-2a (. Pegasys. ). Peginterferon alfa-2a (. Pegasys. ). Summary. NIH SPARE. Phase . 2. Treatment. . Naïve . (unfavorable baseline treatment . characteristics). Osinusi. A, et al. JAMA. 2013;310:804-11.. Source: . Osinusi. A,. . et al. . JAMA. 2013;310:804-11.. VALENCE Trial. Phase . 3. Treatment. Naïve and Treatment . Experienced. Zeuzem. S, et al. . N . Engl. J Med. 2014;370:1993-2001. Source: . Zeuzem. S, et al. N . Engl. J Med. 2014;370:1993-. 2001.. . alfa. -. 2b. . + RBV vs. . Peginterferon alfa-. 2a. . + RBV. IDEAL . STUDY. Phase 3, Treatment Naïve. Treatment. . Naïve, Chronic HCV. McHutchison. JG, et. al. N . Engl. J Med. 2009;361:580-93. . in Genotype 3. ASTRAL-3. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-2 Trial. Source: Foster GR, . ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . NIAID Retreatment. Phase . 2a . Treatment. . Experienced. Osinusi. A, . et al. . Ann Intern Med. 2014;161:634-8.. Source: . Osinusi. A, et al. Ann Intern Med. 2014;161:634-8.. Ledipasvir-Sofosbuvir Retreatment of SOF RBV Failure in HCV GT 1. versus. Interferon alfa-2b + Ribavirin. Phase 3. Treatment. . Naïve, Chronic HCV. Fried MW, . et al. N . Engl. J Med. . 2002;347:975-. 8. 2. .. Peginterferon +/- Ribavirin versus Interferon + . Ribavirin. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT. Following Liver Transplantation. Phase 2. Charlton M, . et al. . Gastroenterology. 2015;148:108-17.. Treatment. Naïve and Treatment . Experienced. Liver Transplantation. Source: Charlton M, et al. Gastroenterology. 2015;148:108-17..

Download Document

Here is the link to download the presentation.
"Sofosbuvir + Peginterferon + Ribavirin in Genotype 2"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.